Heart experts are calling for mandatory cardiac screening after 19-year-old law student Josephine Nasr died in London from a weight-loss drug reaction, an inquest revealed.
Nasr, a California native studying in the UK, suffered a fatal cardiac arrest in September 2025 after taking tirzepatide, a blockbuster GLP-1 weight-loss injection.
A London inquest ruled that drug-induced vomiting caused a severe electrolyte imbalance, which combined with an undiagnosed congenital heart defect called myocardial bridging to trigger a fatal arrhythmia.
Nasr had been prescribed tirzepatide following a telehealth consultation in California during the summer of 2025, despite being only moderately overweight and not obese.
Demands for Heart Screening and FDA Label Updates
Following the tragedy, physicians are urging regulatory authorities to update drug warning labels and asking doctors to screen patients for hidden cardiac conditions before prescribing weight-loss injections.
Dr Michael Aziz, an internal medicine physician at Lenox Hill Hospital in New York City, warned that severe vomiting caused by GLP-1 drugs can rapidly deplete crucial electrolytes such as potassium and magnesium.
"Patients with underlying heart conditions may be particularly vulnerable if they suffer severe vomiting while taking the drugs," Dr Aziz told the Daily Mail. "The risk is very much higher for people with a cardiac condition."
Because electrolyte depletion disrupts the electrical signals that maintain a regular heartbeat, Dr Aziz called on regulators to take action. "I think the FDA should have a labeling update on that," he said.
Dr James Chao, a board-certified surgeon, described the hidden cardiac risk as a "worry" and urged mandatory baseline testing for all new users, including an electrocardiogram (ECG) and a basic metabolic panel blood test.
"Tack on a paragraph, then suggest a baseline ECG and basic metabolic panel and you change medicine for almost zero cost to the system," Dr Chao told the Daily Mail.
Silent Heart Conditions Present Hidden Risks
Medical experts highlighted two common, often-silent heart abnormalities that can trigger fatal outcomes when combined with severe vomiting: myocardial bridging and long QT syndrome.
Myocardial bridging is a congenital defect in which a section of a coronary artery tunnels through heart muscle instead of resting on its surface. Detailed imaging studies indicate the condition may affect up to one in three adults, representing tens of millions of Americans.
While usually harmless, the surrounding heart muscle can squeeze the artery during contractions, restricting blood flow. Standard ECG tests often appear normal, leaving patients unaware of the issue. "The majority of individuals who have it will pass through life without knowing they have it or ever being tested," Dr Chao noted.
Long QT syndrome is an electrical system disorder affecting approximately one in 2,500 people, or roughly 135,000 Americans. It causes the heart to take longer than normal to reset between beats, making patients vulnerable to dangerous out-of-sync rhythms known as torsades de pointes.
FDA Labeling Gaps and Regulatory Limitations
Neither myocardial bridging nor long QT syndrome is currently listed by the U.S. Food and Drug Administration (FDA) as a contraindication for any major GLP-1 weight-loss medication.
The official FDA label for tirzepatide lists formal contraindications only for a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe allergic reactions to the drug.
Although FDA labeling warns that severe gastrointestinal issues, vomiting, and diarrhea can cause dehydration and kidney problems, it contains no specific warning regarding how electrolyte loss affects individuals with underlying arrhythmia risks.
Scrutiny of Online Prescribing for Non-Obese Patients
Nasr's death has also drawn intense scrutiny toward telehealth platforms that supply powerful weight-loss medications to individuals who do not meet clinical guidelines for obesity.
Tirzepatide is FDA-approved for adults with a body mass index (BMI) of 30 or above, or those with a BMI of at least 27 who also suffer from a weight-related health condition such as high blood pressure or type 2 diabetes.
However, the rapid growth of online prescribing services has enabled individuals seeking modest weight reduction to obtain GLP-1 drugs, even though such patients were excluded from clinical safety trials.
In the landmark SURMOUNT-1 trial for tirzepatide, participants had an average starting BMI of around 38. Nearly all were obese, none were normal weight, the study ran for 72 weeks, it excluded patients with type 2 diabetes, and it did not track long-term health after discontinuation.
Gastrointestinal side effects were widespread in the trial, with approximately one in three participants experiencing nausea, one in five reporting diarrhea, and up to one in eight suffering from vomiting.
Body Mass Impact and Calls for Telehealth Reform
Doctors stress that lower body weight increases drug exposure and speeds up dehydration, heightening the risk for lighter patients.
Because smaller individuals have less total body water, fluid lost through vomiting depletes key reserves much faster. "Lighter users are just quicker to deplete," Dr Chao explained, noting that body weight influences tirzepatide concentrations in the bloodstream.
Dr Chao emphasized that the benefit-to-risk ratio becomes difficult to justify for non-obese individuals using the medication for minor weight loss.
"If someone has obesity, there can be enormous health benefits from losing weight, which may justify accepting a very small risk of a serious complication," Dr Chao said. "But if you're already a healthy weight, those benefits largely disappear while the potential risks of taking the drug do not."
Nasr, a second-year law student, fell severely ill just one week after returning to London for school in September 2025. She informed her family of her nausea and vomiting, prompting her sister to try arranging medical care.
When family members could no longer reach her, they requested an emergency welfare check. Responders found Nasr collapsed on her bathroom floor with an empty vial of tirzepatide nearby.
Dr Chao believes her death will ultimately mandate structural changes across online healthcare providers. "I have no doubt telehealth platforms will be forced to adopt this as standard whether they like it or not," he said.
